Pioneers of the world’s first TCR therapy

Dec. 11, 2024 • Time: 7:00 AM EST

EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

Dec. 3, 2024 • Time: 1:00 AM EST

Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma

Nov. 8, 2024 • Time: 7:00 AM EST

Immunocore to present at upcoming investor conferences

Nov. 6, 2024 • Time: 7:00 AM EST

Immunocore reports third quarter financial results and provides a business update

Sep. 14, 2024 • Time: 3:00 AM EDT

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer

Sep. 12, 2024 • Time: 4:05 PM EDT

Immunocore to present at the 2024 Cantor Global Healthcare Conference

Aug. 29, 2024 • Time: 7:00 AM EDT

Immunocore announces transition of Chief Financial Officer

Aug. 8, 2024 • Time: 7:00 AM EDT

Immunocore reports second quarter financial results and provides a business update

Aug. 1, 2024 • Time: 7:00 AM EDT

Immunocore to report second quarter 2024 financial results and host call on August 8, 2024

Jun. 18, 2024 • Time: 7:00 AM EDT

Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma